Small Research Grants for Analyses of Data for the Gabriella Miller Kids First Data Resource (R03)
Funding Opportunity PAR-16-348 from the NIH Guide for Grants and Contracts. The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a pediatric research data resource populated by genome sequence and phenotype data that will be of high value for the communities of investigators who study the genetics of childhood cancers and/or structural birth defects. The overall goal of the Gabriella Miller Kids First Pediatric Data Resource is to help researchers understand the underlying mechanisms of these conditions, leading to more refined diagnostic capabilities and ultimately more targeted therapies, as well as to develop an integrated pediatric research data resource by obtaining and aggregating genome sequence and phenotype data for as many relevant structural birth defects and pediatric cancer cohorts as possible and to advance research in this area through the broad sharing of these data with the research community. This FOA is intended to promote meritorious small research projects focused on the development and analyses of childhood cancer and/or structural birth defects datasets that are part of the Kids First Data Resource or could be included in the Kids First Data Resource. Development of statistical methodology appropriate for analyzing genome-wide data relevant to childhood cancer and/or structural birth defects may also be proposed.
CONCLUSIONS: Survivors of childhood cancer remain at increased risk of a second primary cancer well into adulthood. As the late effects of cancer treatment probably contribute to this risk, treatments need to be refined and their toxicity reduced, without reducing their benefit for survival. PMID: 31743457 [PubMed - as supplied by publisher]
Authors: Grobbelaar C, Ford AM Abstract Acute lymphoblastic leukaemia (ALL) is the most common cancer of childhood. Although the overall survival of children with ALL is now more than 90%, leukaemia remains one of the leading causes of death from disease. In developed countries, the overall survival of patients with ALL has increased to more than 80%; however, those children cured from ALL still show a significant risk of short- and long-term complications as a consequence of their treatment. Accordingly, there is a need not only to develop new methods of diagnosis and prognosis but also to provide patients with le...
Studies in cell and animal models reveal insights into cancer cells ’ vulnerability that could lead to new strategies against brain cancers.
I tried to kill my father for years. To be fair, I was following his wishes. He’d made it clear that when he no longer recognized me, when he could no longer talk, when the nurses started treating him like a toddler, he didn’t want to live any longer. My father was 58 years old when he was diagnosed with Alzheimer’s disease. He took the diagnosis with the self-deprecating humor he’d spent a lifetime cultivating, constantly cracking jokes about how he would one day turn into a zombie, a walking corpse. We had a good 10 years with him after the diagnosis. Eventually, his jokes came true. Seven years ...
[Ghanaian Times] About 328 childhood cancer cases have been recorded at the Korle Bu and Komfo Anokye Teaching Hospitals in Accra and Kumasi respectively between January and October this year.
(NIH/National Center for Advancing Translational Sciences (NCATS)) Researchers have devised a new, promising plan of attack against deadly childhood brain cancers called diffuse midline gliomas (DMG). NCATS and Stanford University scientists and their colleagues showed that combining two drugs killed DMG patient cells grown in the laboratory and in animal models. The drugs countered the effects of a genetic mutation that causes the diseases. Their studies also uncovered an unrecognized vulnerability in the cancer cells that scientists may be able to exploit.
With significant improvements in the survival rates for most childhood cancers, there is increased pressure to determine how follow-up or aftercare for survivors is best structured.
This study provides a comprehensive single-agent and combinatorial drug screen for DMG and identifies concomitant HDAC and proteasome inhibition as a promising therapeutic strategy that underscores underrecognized metabolic vulnerabilities in DMG.
Mosaic-variegated aneuploidy (MVA) syndrome is a rare childhood disorder characterized by biallelic BUBR1, CEP57, or TRIP13 aberrations; increased chromosome missegregation; and a broad spectrum of clinical features, including various cancers, congenital defects, and progeroid pathologies. To investigate the mechanisms underlying this disorder and its phenotypic heterogeneity, we mimicked the BUBR1L1012P mutation in mice (BubR1L1002P) and combined it with 2 other MVA variants, BUBR1X753 and BUBR1H, generating a truncated protein and low amounts of wild-type protein, respectively. Whereas BubR1X753/L1002P and BubR1H/X753 mi...
Only a few months after announcing that it will cease production of this essential medicine for childhood cancers, Teva has announced it will jump back into the market.Medscape Medical News